Which has preferable valuation and earnings, HBIO or SEER?

Harvard Bioscience has higher revenue and earnings than Seer. Harvard Bioscience is trading at a lower price-to-earnings ratio than Seer, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Harvard Bioscience $86.55M 0.42 -$56.70M -$2.31 N/A Seer $16.58M 6.38 -$73.60M -$1.22 N/A

Is HBIO or SEER more profitable?

Harvard Bioscience has a net margin of -11.86% compared to Seer's net margin of -478.05%. Seer's return on equity of -27.23% beat Harvard Bioscience's return on equity. Company Net Margins Return on Equity Return on Assets Harvard Bioscience -11.86% -33.13% -4.80% Seer -478.05% -27.23% -23.99%

Do analysts recommend HBIO or CSBR?

Harvard Bioscience currently has a consensus target price of $6.75, indicating a potential downside of 15.20%. Given Harvard Bioscience's stronger consensus rating and higher possible upside, equities analysts plainly believe Harvard Bioscience is more favorable than Champions Oncology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Harvard Bioscience 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Champions Oncology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Harvard Bioscience (HBIO) Competitors

$7.96 -0.06 (-0.75%)

Closing price 09/25/2026 04:00 PM Eastern

Extended Trading

$7.60 -0.36 (-4.57%)

As of 09/25/2026 07:56 PM Eastern

Compare

HBIO vs. QTRX, MXCT, NAUT, SEER, and CSBR

Should you buy Harvard Bioscience stock or one of its competitors? Harvard Bioscience's main competitors and comparable companies include Quanterix (QTRX), MaxCyte (MXCT), Nautilus Biotechnology (NAUT), Seer (SEER), and Champions Oncology (CSBR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does Harvard Bioscience compare to Quanterix?

Harvard Bioscience (NASDAQ:HBIO) and Quanterix (NASDAQ:QTRX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, risk, earnings, institutional ownership, media sentiment, analyst recommendations, profitability and dividends.

80.9% of Harvard Bioscience shares are held by institutional investors. Comparatively, 86.5% of Quanterix shares are held by institutional investors. 17.0% of Harvard Bioscience shares are held by insiders. Comparatively, 1.5% of Quanterix shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Harvard Bioscience presently has a consensus target price of $6.75, suggesting a potential downside of 15.20%. Quanterix has a consensus target price of $3.00, suggesting a potential downside of 8.26%. Given Quanterix's higher probable upside, analysts clearly believe Quanterix is more favorable than Harvard Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Harvard Bioscience	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Quanterix	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Harvard Bioscience has higher earnings, but lower revenue than Quanterix. Harvard Bioscience is trading at a lower price-to-earnings ratio than Quanterix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Harvard Bioscience	$86.55M	0.42	-$56.70M	-$2.31	N/A
Quanterix	$138.90M	1.11	-$107.15M	-$2.63	N/A

In the previous week, Quanterix had 3 more articles in the media than Harvard Bioscience. MarketBeat recorded 4 mentions for Quanterix and 1 mentions for Harvard Bioscience. Harvard Bioscience's average media sentiment score of 0.91 beat Quanterix's score of 0.47 indicating that Harvard Bioscience is being referred to more favorably in the media.

Company	Overall Sentiment
Harvard Bioscience	Positive
Quanterix	Neutral

Harvard Bioscience has a net margin of -11.86% compared to Quanterix's net margin of -80.25%. Quanterix's return on equity of -26.09% beat Harvard Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Harvard Bioscience	-11.86%	-33.13%	-4.80%
Quanterix	-80.25%	-26.09%	-19.03%

Harvard Bioscience has a beta of 1.53, indicating that its share price is 53% more volatile than the broader market. Comparatively, Quanterix has a beta of 1.04, indicating that its share price is 4% more volatile than the broader market.

Summary

Harvard Bioscience beats Quanterix on 9 of the 16 factors compared between the two stocks.

How does Harvard Bioscience compare to MaxCyte?

MaxCyte (NASDAQ:MXCT) and Harvard Bioscience (NASDAQ:HBIO) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, dividends, analyst recommendations, media sentiment, profitability, risk, institutional ownership and valuation.

MaxCyte has a beta of 1.52, suggesting that its share price is 52% more volatile than the broader market. Comparatively, Harvard Bioscience has a beta of 1.53, suggesting that its share price is 53% more volatile than the broader market.

68.8% of MaxCyte shares are owned by institutional investors. Comparatively, 80.9% of Harvard Bioscience shares are owned by institutional investors. 4.1% of MaxCyte shares are owned by insiders. Comparatively, 17.0% of Harvard Bioscience shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, MaxCyte had 2 more articles in the media than Harvard Bioscience. MarketBeat recorded 3 mentions for MaxCyte and 1 mentions for Harvard Bioscience. Harvard Bioscience's average media sentiment score of 0.91 beat MaxCyte's score of 0.61 indicating that Harvard Bioscience is being referred to more favorably in the news media.

Company	Overall Sentiment
MaxCyte	Positive
Harvard Bioscience	Positive

Harvard Bioscience has a net margin of -11.86% compared to MaxCyte's net margin of -114.77%. MaxCyte's return on equity of -18.92% beat Harvard Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MaxCyte	-114.77%	-18.92%	-16.14%
Harvard Bioscience	-11.86%	-33.13%	-4.80%

MaxCyte presently has a consensus price target of $5.00, suggesting a potential upside of 327.35%. Harvard Bioscience has a consensus price target of $6.75, suggesting a potential downside of 15.20%. Given MaxCyte's higher probable upside, equities analysts plainly believe MaxCyte is more favorable than Harvard Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MaxCyte	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Harvard Bioscience	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

MaxCyte has higher earnings, but lower revenue than Harvard Bioscience. MaxCyte is trading at a lower price-to-earnings ratio than Harvard Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MaxCyte	$33.03M	3.66	-$44.63M	-$0.33	N/A
Harvard Bioscience	$86.55M	0.42	-$56.70M	-$2.31	N/A

Summary

Harvard Bioscience beats MaxCyte on 8 of the 14 factors compared between the two stocks.

How does Harvard Bioscience compare to Nautilus Biotechnology?

Harvard Bioscience (NASDAQ:HBIO) and Nautilus Biotechnology (NASDAQ:NAUT) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, valuation, media sentiment, profitability, analyst recommendations and risk.

Harvard Bioscience has a beta of 1.53, indicating that its stock price is 53% more volatile than the broader market. Comparatively, Nautilus Biotechnology has a beta of 0.87, indicating that its stock price is 13% less volatile than the broader market.

Harvard Bioscience currently has a consensus target price of $6.75, indicating a potential downside of 15.20%. Nautilus Biotechnology has a consensus target price of $4.00, indicating a potential upside of 315.50%. Given Nautilus Biotechnology's stronger consensus rating and higher possible upside, analysts plainly believe Nautilus Biotechnology is more favorable than Harvard Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Harvard Bioscience	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Nautilus Biotechnology	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

80.9% of Harvard Bioscience shares are held by institutional investors. Comparatively, 50.7% of Nautilus Biotechnology shares are held by institutional investors. 17.0% of Harvard Bioscience shares are held by insiders. Comparatively, 41.1% of Nautilus Biotechnology shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Harvard Bioscience and Harvard Bioscience both had 1 articles in the media. Nautilus Biotechnology's average media sentiment score of 1.82 beat Harvard Bioscience's score of 0.91 indicating that Nautilus Biotechnology is being referred to more favorably in the news media.

Company	Overall Sentiment
Harvard Bioscience	Positive
Nautilus Biotechnology	Very Positive

Nautilus Biotechnology has a net margin of 0.00% compared to Harvard Bioscience's net margin of -11.86%. Harvard Bioscience's return on equity of -33.13% beat Nautilus Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Harvard Bioscience	-11.86%	-33.13%	-4.80%
Nautilus Biotechnology	N/A	-37.58%	-30.83%

Harvard Bioscience has higher revenue and earnings than Nautilus Biotechnology. Harvard Bioscience is trading at a lower price-to-earnings ratio than Nautilus Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Harvard Bioscience	$86.55M	0.42	-$56.70M	-$2.31	N/A
Nautilus Biotechnology	N/A	N/A	-$59M	-$0.45	N/A

Summary

Nautilus Biotechnology beats Harvard Bioscience on 8 of the 14 factors compared between the two stocks.

How does Harvard Bioscience compare to Seer?

Harvard Bioscience (NASDAQ:HBIO) and Seer (NASDAQ:SEER) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, institutional ownership, earnings, profitability, analyst recommendations, dividends, valuation and risk.

Harvard Bioscience has a beta of 1.53, indicating that its share price is 53% more volatile than the broader market. Comparatively, Seer has a beta of 1.5, indicating that its share price is 50% more volatile than the broader market.

In the previous week, Seer had 8 more articles in the media than Harvard Bioscience. MarketBeat recorded 9 mentions for Seer and 1 mentions for Harvard Bioscience. Harvard Bioscience's average media sentiment score of 0.91 beat Seer's score of 0.50 indicating that Harvard Bioscience is being referred to more favorably in the media.

Company	Overall Sentiment
Harvard Bioscience	Positive
Seer	Positive

Harvard Bioscience has a net margin of -11.86% compared to Seer's net margin of -478.05%. Seer's return on equity of -27.23% beat Harvard Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Harvard Bioscience	-11.86%	-33.13%	-4.80%
Seer	-478.05%	-27.23%	-23.99%

80.9% of Harvard Bioscience shares are held by institutional investors. Comparatively, 75.2% of Seer shares are held by institutional investors. 17.0% of Harvard Bioscience shares are held by company insiders. Comparatively, 11.3% of Seer shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Harvard Bioscience presently has a consensus price target of $6.75, indicating a potential downside of 15.20%. Seer has a consensus price target of $4.00, indicating a potential upside of 109.42%. Given Seer's stronger consensus rating and higher probable upside, analysts clearly believe Seer is more favorable than Harvard Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Harvard Bioscience	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Seer	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	2 Strong Buy rating(s)	3.00

Harvard Bioscience has higher revenue and earnings than Seer. Harvard Bioscience is trading at a lower price-to-earnings ratio than Seer, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Harvard Bioscience	$86.55M	0.42	-$56.70M	-$2.31	N/A
Seer	$16.58M	6.38	-$73.60M	-$1.22	N/A

Summary

Harvard Bioscience beats Seer on 9 of the 17 factors compared between the two stocks.

How does Harvard Bioscience compare to Champions Oncology?

Harvard Bioscience (NASDAQ:HBIO) and Champions Oncology (NASDAQ:CSBR) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, earnings, media sentiment, profitability, analyst recommendations, risk and valuation.

In the previous week, Champions Oncology had 1 more articles in the media than Harvard Bioscience. MarketBeat recorded 2 mentions for Champions Oncology and 1 mentions for Harvard Bioscience. Champions Oncology's average media sentiment score of 0.94 beat Harvard Bioscience's score of 0.91 indicating that Champions Oncology is being referred to more favorably in the news media.

Company	Overall Sentiment
Harvard Bioscience	Positive
Champions Oncology	Positive

Harvard Bioscience has a beta of 1.53, indicating that its share price is 53% more volatile than the broader market. Comparatively, Champions Oncology has a beta of 0.4, indicating that its share price is 60% less volatile than the broader market.

Champions Oncology has a net margin of -1.82% compared to Harvard Bioscience's net margin of -11.86%. Champions Oncology's return on equity of -25.77% beat Harvard Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Harvard Bioscience	-11.86%	-33.13%	-4.80%
Champions Oncology	-1.82%	-25.77%	-3.71%

Champions Oncology has lower revenue, but higher earnings than Harvard Bioscience. Champions Oncology is trading at a lower price-to-earnings ratio than Harvard Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Harvard Bioscience	$86.55M	0.42	-$56.70M	-$2.31	N/A
Champions Oncology	$59.42M	1.15	-$1.17M	-$0.08	N/A

80.9% of Harvard Bioscience shares are owned by institutional investors. Comparatively, 41.3% of Champions Oncology shares are owned by institutional investors. 17.0% of Harvard Bioscience shares are owned by company insiders. Comparatively, 46.3% of Champions Oncology shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Harvard Bioscience currently has a consensus target price of $6.75, indicating a potential downside of 15.20%. Given Harvard Bioscience's stronger consensus rating and higher possible upside, equities analysts plainly believe Harvard Bioscience is more favorable than Champions Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Harvard Bioscience	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Champions Oncology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Champions Oncology beats Harvard Bioscience on 9 of the 16 factors compared between the two stocks.

Get Harvard Bioscience News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HBIO vs. The Competition

Export

Metric	Harvard Bioscience	Life Sciences Tools & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$36.51M	$10.94B	$7.29B	$13.11B
Dividend Yield	N/A	1.45%	2.52%	13.50%
P/E Ratio	-3.45	73.84	275.27	25.78
Price / Sales	0.42	108.00	613.85	83.77
Price / Cash	0.68	27.70	79.23	52.93
Price / Book	2.59	6.07	10.44	6.30
Net Income	-$56.70M	$56.67B	$3.50B	$360.35M
7 Day Performance	0.13%	2.34%	-1.31%	-0.23%
1 Month Performance	4.05%	2.53%	-4.72%	-3.87%
1 Year Performance	79.32%	41.07%	14.97%	5.38%

Harvard Bioscience Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HBIO Harvard Bioscience	1.124 of 5 stars	$7.96 -0.7%	$6.75 -15.2%	+81.2%	$36.51M	$86.55M	N/A	339
QTRX Quanterix	0.5943 of 5 stars	$2.72 +8.8%	$3.00 +10.3%	-37.8%	$128.63M	$138.90M	N/A	460	News Coverage
MXCT MaxCyte	3.4525 of 5 stars	$1.19 +1.3%	$5.00 +320.2%	-23.5%	$122.82M	$31.05M	N/A	80	Analyst Upgrade
NAUT Nautilus Biotechnology	2.6665 of 5 stars	$0.89 -1.7%	$4.00 +348.9%	+17.1%	$113.40M	$10K	N/A	130	Positive News
SEER Seer	3.6049 of 5 stars	$1.90 -0.5%	$4.00 +110.5%	-13.2%	$105.21M	$13.75M	N/A	160	Short Interest Decrease

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:HBIO) was last updated on 9/26/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Harvard Bioscience (HBIO) Competitors

HBIO vs. QTRX, MXCT, NAUT, SEER, and CSBR

How does Harvard Bioscience compare to Quanterix?

Summary

How does Harvard Bioscience compare to MaxCyte?

Summary

How does Harvard Bioscience compare to Nautilus Biotechnology?

Summary

How does Harvard Bioscience compare to Seer?

Summary

How does Harvard Bioscience compare to Champions Oncology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HBIO vs. The Competition

Harvard Bioscience Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Harvard Bioscience (HBIO) Competitors

HBIO vs. QTRX, MXCT, NAUT, SEER, and CSBR

How does Harvard Bioscience compare to Quanterix?

Do insiders and institutionals believe in HBIO or QTRX?

Do analysts rate HBIO or QTRX?

Which has stronger valuation and earnings, HBIO or QTRX?

Does the media refer more to HBIO or QTRX?

Is HBIO or QTRX more profitable?

Which has more risk and volatility, HBIO or QTRX?

Summary

How does Harvard Bioscience compare to MaxCyte?

Which has more volatility and risk, MXCT or HBIO?

Do insiders & institutionals hold more shares of MXCT or HBIO?

Does the media prefer MXCT or HBIO?

Is MXCT or HBIO more profitable?

Do analysts rate MXCT or HBIO?

Which has preferable earnings & valuation, MXCT or HBIO?

Summary

How does Harvard Bioscience compare to Nautilus Biotechnology?

Which has more risk & volatility, HBIO or NAUT?

Do analysts rate HBIO or NAUT?

Do insiders and institutionals believe in HBIO or NAUT?

Does the media refer more to HBIO or NAUT?

Is HBIO or NAUT more profitable?

Which has higher valuation & earnings, HBIO or NAUT?

Summary

How does Harvard Bioscience compare to Seer?

Which has more risk and volatility, HBIO or SEER?

Does the media refer more to HBIO or SEER?

Is HBIO or SEER more profitable?

Do institutionals & insiders believe in HBIO or SEER?

Do analysts rate HBIO or SEER?

Which has preferable valuation and earnings, HBIO or SEER?

Summary

How does Harvard Bioscience compare to Champions Oncology?

Does the media prefer HBIO or CSBR?

Which has more volatility and risk, HBIO or CSBR?

Is HBIO or CSBR more profitable?

Which has stronger earnings & valuation, HBIO or CSBR?

Do institutionals and insiders believe in HBIO or CSBR?

Do analysts recommend HBIO or CSBR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HBIO vs. The Competition

Harvard Bioscience Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools